1.18 - Benefits and risks of CVD treatments

Targets and trade-offs

Cardiovascular treatments act on different processes that can threaten the blood supply to tissues.

Atherosclerosis forms plaques in artery walls. High blood pressure increases the strain on the heart and vessels. If a plaque ruptures, platelet aggregation and the clotting reactions can produce a thrombus that obstructs blood flow. Tissue beyond a persistent blockage receives too little oxygen and may be damaged. These are related processes, but reducing one of them is not the same as reducing all of them.

A medicine's benefit is an improvement it can produce, such as a lower probability of a heart attack. A risk of treatment is the probability of an unwanted harmful effect. An adverse effect is an unwanted harmful effect that occurs. Benefits and risks concern both likelihood and severity: mild indigestion and a major internal bleed are not equivalent consequences.

The four named classes are antihypertensives, statins, anticoagulants and platelet inhibitors. The first two principally reduce contributors to cardiovascular disease; the last two interfere with different interacting parts of clot formation. The treatment's effect should therefore be explained as a chain: the process it changes → the change in circulation → the benefit or harm.

Reducing CVD risk does not guarantee that an event will never happen. Conversely, the possibility of an adverse effect does not mean every treated person will experience it. The examples below explain biology; a treatment choice for an individual requires clinical assessment of that person's circumstances.

Antihypertensives and pressure

Antihypertensives lower abnormally high blood pressure, reducing strain on the heart and blood vessels.

Hypertension means persistently high blood pressure. An antihypertensive is a medicine used to lower it. This is a broad class: its members do not all act by the same mechanism. One example is ramipril, an angiotensin-converting enzyme, or ACE, inhibitor.

ACE helps form angiotensin II, a signalling substance that makes blood vessels constrict. The active form of ramipril inhibits ACE, so less angiotensin II is formed. Arterioles relax and widen: vasodilation. Wider arterioles offer less resistance to blood flow, so arterial blood pressure falls. This mechanism is supported by the manufacturer's ramipril product information.

Lower pressure reduces the force acting on artery walls and the pressure against which the heart must pump. This helps reduce the risk of cardiovascular events, including heart attacks and strokes. It does not mean ramipril physically removes a plaque or dissolves a thrombus. The NHS account of ramipril links vessel widening to lower pressure and easier pumping.

The pressure-lowering effect also explains one risk. If pressure falls too far, the blood supply to the brain can become inadequate, causing dizziness or fainting. ACE inhibitors can also cause a persistent dry cough. Kidney function and blood potassium can change, so blood tests as well as pressure measurements may be used to monitor treatment. These are examples associated with ACE inhibitors; a dry cough is not a universal property of every antihypertensive. NHS ramipril information describes these monitoring needs and possible effects.

Statins and LDL

Statins reduce circulating LDL cholesterol by altering cholesterol production and uptake in the liver.

LDL, or low-density lipoprotein, transports cholesterol in the blood. A high LDL cholesterol concentration contributes to cholesterol accumulation in artery walls and atherosclerosis. Cholesterol remains useful for normal cell functions; the aim is to reduce harmful excess and cardiovascular risk, not remove all cholesterol.

Statins, such as atorvastatin, inhibit HMG-CoA reductase, an enzyme in the liver's cholesterol-synthesis pathway. The liver makes less cholesterol and increases the number of LDL receptors on its cell surfaces. These receptors help liver cells take up LDL from the blood. Together these changes lower blood LDL cholesterol. The atorvastatin product information describes both the enzyme inhibition and increased LDL uptake.

Lower LDL reduces a contributor to plaque development and progression, helping lower the risk of heart attacks and ischaemic strokes. This is a preventive effect over time, not an immediate opening of a blocked artery. A statin does not stop platelet aggregation by the same mechanism as aspirin. The NHS statin overview explains their use in people at increased CVD risk and in people who already have CVD to reduce further events.

Possible adverse effects include digestive problems and muscle symptoms. Serious muscle injury is rare. Liver enzymes in the blood can rise, and liver effects are a reason for appropriate monitoring. Other medicines can increase the chance of some adverse effects by changing statin exposure. These risks must be weighed against the cardiovascular benefit; they do not show that all statin users develop muscle or liver damage. NHS side-effect information distinguishes possible symptoms from rare muscle damage.

Anticoagulants and fibrin

Anticoagulants interfere with the clotting reactions that produce the fibrin reinforcement of a blood clot.

In the simplified clotting sequence, prothrombin is converted to thrombin. Thrombin then catalyses the conversion of soluble fibrinogen to insoluble fibrin. Fibrin fibres form a mesh that reinforces the platelet plug and traps blood cells.

Warfarin is one anticoagulant. Vitamin K is needed for the liver to produce functional forms of several clotting factors, including prothrombin. Warfarin interferes with vitamin K recycling, so fewer functional vitamin K-dependent clotting factors are produced. This reduces the capacity of the clotting pathway to generate thrombin and then fibrin. It is not correct to say that warfarin directly destroys all fibrinogen or blocks platelet adhesion. The warfarin product information describes its effect on active clotting factors.

The benefit is a reduced probability of a harmful clot forming or an existing clot extending. A clot formed in the heart, for example during some abnormal heart rhythms, can travel and block an artery supplying the brain. Appropriate anticoagulation reduces this clot-related stroke risk. Anticoagulants do not directly dissolve an established thrombus; limiting further clot formation allows the body's own processes to remove clot material over time. The NHS anticoagulant overview distinguishes anticoagulants from antiplatelet drugs and explains their clot-prevention role.

The same interference with coagulation makes normal wound sealing less effective, increasing the risk of prolonged or internal bleeding. The balance can change with other medicines, diet or disease. Warfarin therefore requires blood-clotting measurements, reported as the international normalised ratio, or INR, to monitor its effect. INR measures clotting behaviour; it is not a measurement of blood viscosity. Monitoring requirements differ between anticoagulants, so warfarin's INR checks must not be presented as a rule for every member of the class. NHS Specialist Pharmacy Service describes warfarin monitoring.

Platelet inhibitors and aggregation

Platelet inhibitors reduce platelet activation and aggregation, making a platelet plug less able to develop.

Platelet inhibitors, also called antiplatelet medicines, act on platelets rather than using warfarin's vitamin K mechanism. Platelets are small cell fragments that adhere at vessel damage. Activation makes them release signals that recruit further platelets, and aggregation is their sticking together to form a plug. This process interacts with the fibrin-producing clotting reactions, but a platelet plug and a fibrin mesh are different structures.

One example is low-dose aspirin. It inhibits a platelet enzyme called cyclooxygenase, reducing production of thromboxane A₂, a substance that promotes platelet activation and aggregation. Consequently, platelets are less able to recruit and aggregate with one another. Aspirin's inhibition of this enzyme is irreversible in an affected platelet. This explains a persistent antiplatelet effect without claiming that aspirin removes platelets from the blood. The aspirin product information describes this mechanism. Other platelet inhibitors can act on different platelet signalling pathways; the shared result is reduced activation or aggregation.

After a plaque ruptures, platelet aggregation can help initiate a thrombus in an artery. Reducing aggregation therefore lowers the risk that a dangerous obstruction develops, helping prevent heart attacks and clot-related strokes in appropriate clinical circumstances. A platelet inhibitor does not lower LDL by inhibiting cholesterol synthesis, nor does it physically remove the plaque.

Normal platelet plugs also help seal vessel damage. Reduced aggregation can therefore cause easier bruising or more prolonged bleeding. Aspirin can additionally cause indigestion, stomach ulcers and gastrointestinal bleeding; those stomach effects are specific examples for aspirin rather than the identical side-effect profile of every antiplatelet drug. NHS aspirin information supports both the preventive benefit and these possible harms.

The useful distinction is the target: anticoagulants reduce coagulation and fibrin formation; platelet inhibitors reduce platelet activation and aggregation. Calling either a “blood thinner” can obscure this distinction, because neither works simply by making the blood physically thinner. Combining effects on both processes can also increase bleeding risk.

Weighing benefit and harm

A useful comparison links each treatment's biological target to its benefit and then to the harm that may limit its use.

Different targets explain why more than one class may be useful in the same disease: lowering LDL addresses a contributor to plaque development, while reducing platelet aggregation addresses clot formation on a damaged plaque. One class is not automatically a substitute for another. The extra benefit and possible interactions or combined harms still have to be assessed.

Reading a claim about treatment

Consider this complete original NovaLearn practice summary, using invented data rather than results for a real medicine:

“In a comparison of two similar groups followed for the same five years, 40 in every 1,000 people in the comparison group had a clot-related cardiovascular event. In the group given a platelet inhibitor, 30 in every 1,000 had such an event. Major bleeding occurred in 4 in every 1,000 in the comparison group and 7 in every 1,000 in the treated group. A headline described the treatment as preventing one quarter of cardiovascular events. The summary gives no uncertainty estimates.”

The absolute event reduction is 40 − 30 = 10 per 1,000 people over five years, or one percentage point: 4% falls to 3%. The relative reduction is 10 ÷ 40 × 100 = 25%. The headline expresses the relative reduction. It does not mean 25 out of every 100 treated people avoided an event; the observed absolute difference is 1 out of every 100.

The excess major bleeding is 7 − 4 = 3 per 1,000 over five years, or 0.3 percentage points. Thus the supplied results show fewer clot-related events alongside more major bleeding. Reduced platelet aggregation offers a plausible mechanism for both effects. A lower event rate alone would give an incomplete account of the treatment.

The two differences should not simply be subtracted and called a guaranteed net benefit of seven people. An event and a bleed may differ in severity, and the same person might experience both. Uncertainty, study quality and whether the groups resemble the population of interest also affect confidence in the estimate. These data permit a comparison for the stated groups and period, not a prediction that every individual will benefit.

Baseline risk is the risk without the added treatment in the stated comparison. If another group has a baseline event risk of only 8 per 1,000 over five years, the same assumed 25% relative reduction would prevent 8 × 0.25 = 2 events per 1,000. The smaller absolute benefit could change the balance against treatment harm. This is a numerical illustration, not evidence that the actual effect or bleeding rate must be identical in different populations.

A reasoned conclusion names the particular benefit, the particular risk and what the evidence can support. It avoids treating a relative-risk headline or a list of side effects as a complete answer.